# OCT vs. Angiography in Complex Lesions: ILUMIEN IV

#### Ziad A Ali MD DPhil

St Francis Hospital & Heart Center
Cardiovascular Research Foundation, New York, USA

zali@crf.org
Follow me @ziadalinyc





#### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship	Company
Grant/Research Support (Institutional)	NIH/NHLBI, Abbott, Philips, Boston Scientific, Abiomed, Opsens, Acist Medical, Medtronic Cardiovascular Systems Inc
Consulting Fees/Honoraria	Amgen, Astra Zeneca, Boston Scientific
Equity	Shockwave Medical








#### **Background; ILUMIEN IV**



#### **Post-procedure OCT Findings**

Variables	OCT L=1222	Angio L=1328	Difference (95% CI)
MSA, mm <sup>2</sup>	5.72 ± 2.04	5.36 ± 1.87	0.36 (0.21, 0.51)
Min stent expansion, %	80.8 ± 16.8	$78.0 \pm 16.7$	2.9 (1.6, 4.2)
Mean stent expansion, %	111.3 ± 16.3	103.0 ± 17.2	8.2 (6.9, 9.5)
Stent expansion			
<ul><li>Acceptable (≥90%)</li></ul>	40.5%	23.3%	17.2% (13.6, 20.8)
Dissection, any	32.0%	34.2%	-2.2% (-5.9, 1.4)
Major	2.9%	5.1%	-2.2% (-3.9, -0.6)
Minor	22.7%	19.4%	3.3% (-0.1, 6.6)
Malapposition, any	55.3%	69.7%	-14.4% (-18.1, -10.6)
Major	15.8%	33.2%	-17.4% (-20.6, -14.1)
Minor	39.4%	36.5%	3.0% (-0.8, 6.7)
Tissue Protrusion, any	55.9%	47.0%	8.9% (5.0, 12.8)
Major	5.3%	8.3%	-3.0% (-4.9, -1.0)
Minor	50.6%	38.7%	11.9% (8.1, 15.7)
Reference Disease, any	17.3%	20.1%	-2.8% (-5.9, 0.3)
Focal	9.5%	12.1%	-2.7% (-5.1, -0.2)
Diffuse	7.8%	8.0%	-0.1% (-2.3, 2.0)

#### **Target Vessel Failure**






## What did we learn?

## **Sub-group Analysis**





## **Covid Impact**

#### **Target Vessel Failure**


Pre-Covid (n=476) 7 Covid (n=2020) 7


#### **OCT** Angiography

7.2% 10.1% 7.5% 7.7%

#### Hazard Ratio [95% CI]









## 2-Year Clinical Outcomes



	OCT (n=1233)	Angio (n=1254)	Hazard Ratio (95% CI)
All-cause mortality	2.7%	3.6%	0.73 (0.47, 1.16)
-Cardiac	0.8%	1.3%	0.57 (0.25, 1.29)
-Vascular	0.3%	0.3%	0.76 (0.17, 3.38)
-Non-cardiovascular	1.7%	2.0%	0.84 (0.46, 1.52)
All MI	4.8%	6.0%	0.80 (0.56, 1.13)
-TV-MI	2.5%	3.3%	0.77 (0.48, 1.22)
-Periprocedural MI	1.4%	1.7%	0.82 (0.43, 1.56)
-Non-periprocedural MI	3.4%	4.4%	0.77 (0.51, 1.17)
All revascularization	9.4%	10.1%	0.94 (0.72, 1.21)
- ID-TVR			0.99 (0.71, 1.40)
- ID-TLR			1.05 (0.71, 1.54)
- ID-TVR/non-TLR			0.79 (0.45, 1.38)

## Study design



#### Aim:


To determine whether OCT-guided PCI improves procedural and clinical outcomes compared with angiography-guided PCI, specifically in complex angiographic lesions, assessing for hard endpoints.

#### **Method:**

- This was a pre-specified powered analysis of the ILUMIEN IV: OPTIMAL PCI, a prospective, single-blind randomized trial comparing OCT-guided versus angiography-guided PCI.
- Complex angiographic lesions included;
- Long or multiple lesion (stent ≥28 mm)
- Two-stent bifurcation lesion
- 3. Severely calcified lesion
- Chronic total occlusion
- In-stent restenosis

## **Study Flowchart**





#### **Endpoints**

- Imaging endpoint:
- Final post-PCI MSA assessed by OCT
- 2. Major clinical endpoints:
- Serious Major Adverse Cardiovascular Events (MACE) during 2-years follow up

(a composite of cardiac death, target-vessel MI, or definite/probable stent thrombosis)

• Target-Vessel Failure (TVF) during 2-years follow-up (a composite of cardiac death, target-vessel MI, or ischemia-driven TVR)

#### **Baseline characteristics**



	OCT-Guided PCI (N=992)	Angiography-Guided PCI (N=981)	P-value
Ago voore	$65.6 \pm 10.5$	65.7 ± 10.4	0.89
Age, years			
Male	792 (79.8%)	750 (76.5%)	0.07
Hypertension	707 (71.3%)	734 (74.8%)	0.08
Dyslipidemia	658 (66.3%)	681 (69.4%)	0.14
Diabetes mellitus	360 (36.3%)	342 (34.9%)	0.51
Current smoker	198/991 (20.0%)	192/980 (19.6%)	0.83
PVD	56 (5.6%)	62 (6.3%)	0.53
Prior MI	211 (21.3%)	255 (26.0%)	0.01
Prior CABG	53 (5.3%)	43 (4.4%)	0.32
Renal insufficiency	86 (8.7%)	90 (9.2%)	0.69
LVEF, %	$55.1 \pm 8.5$	$55.0 \pm 8.7$	0.88
Clinical presentation			
Silent ischemia	140 (14.1%)	151 (15.4%)	0.42
Stable angina	288 (29.0%)	303 (30.9%)	0.37
Unstable angina	297 (29.9%)	281 (28.6%)	0.53
NSTEMI	208 (21.0%)	181 (18.5%)	0.16
Recent STEMI (>24 hours)	59 (5.9%)	65 (6.6%)	0.53

# **Qualifying Characteristics**



	OCT-Guided PCI (N=992)	Angiography-Guided PCI (N=981)	P-value
Long or multiple lesions	853 (86.0%)	824 (84.0%)	0.22
Two-stent bifurcation	40 (4.0%)	43 (4.4%)	0.70
Severe calcification	140 (14.1%)	146 (14.9%)	0.63
Chronic total occlusion	94 (9.5%)	79 (8.1%)	0.26
Diffuse or multi-focal ISR	130 (13.1%)	138 (14.1%)	0.53

## **Baseline Angiographic Characteristics**



	OCT-Guided PCI (L=1075)	Angiography-Guided PCI (L=1095)	P-Value
Target vessel			0.69
LAD	571 (53.1%)	575 (52.5%)	
LCX	190 (17.7%)	209 (19.1%)	
RCA	314 (29.2%)	311 (28.4%)	
Thrombus	76/1072 (7.1%)	77/1082 (7.1%)	0.98
Severe calcification	363/1069 (34.0%)	348/1080 (32.2%)	0.39
Reference vessel diameter, mm	$2.92\pm0.43$	$2.90\pm0.42$	0.28
Minimum lumen diameter, mm	$0.87\pm0.43$	$0.87\pm0.43$	0.76
Diameter stenosis, %	$70.2 \pm 14.0$	69.8 ± 14.0	0.58
Lesion length, mm	$36.0 \pm 15.5$	33.3 ± 16.1	<0.001
Baseline TIMI III flow	832/1032 (80.6%)	815/1034 (78.8%)	0.31

## **Procedural Characteristics per patient**



	OCT-Guided PCI (N=992)	Angiography-Guided PCI (N=981)	P-value
Radial access	716 (72.2%)	710 (72.4%)	0.92
Total stent length, mm	49.0 ± 23.5	45.4 ± 24.2	0.001
Procedure duration, min	$72.0 \pm 39.2$	$53.9 \pm 37.1$	<0.001
Fluoroscopy duration, min	22.3 ± 13.9	$18.4 \pm 12.1$	<0.001
Radiation dose, Gy	2.1 ± 1.8	1.6 ± 1.3	<0.001
Contrast volume, mL	237.7 ± 88.8	200.4 ± 82.1	<0.001

## **Procedural Characteristics per lesion**



	OCT-Guided PCI (L=1105)	Angiography-Guided PCI (L=1116)	P-value	
Advanced lesion preparation	163 (14.8%)	101 (9.1%)	<0.001	
Maximum stent diameter, mm	$3.22\pm0.47$	$3.12\pm0.39$	<0.001	
Post-dilatation performed	1064 (96.3%)	957 (85.8%)	<0.001	
Post-dilatation balloons used	1.7 ± 1.2	1.5 ± 1.2	<0.001	
Maximum device size, mm	$3.68\pm0.55$	$3.39\pm0.46$	<0.001	
Maximum inflation pressure,atm	$20.0\pm3.1$	$18.6 \pm 3.4$	<0.001	
Stent type				
Xience stent	1086/1094 (99.3%)	1106/1112 (99.5%)	0.57	
Other or not specified	18/1094 (1.6%)	12/1112 (1.1%)	0.25	

## **Post-PCI Angiographic Characteristics**



	OCT-Guided PCI (L=1075)	Angiography-Guided PCI (L=1095)	P-value
Reference vessel diameter, mm	$2.96 \pm 0.44$	$2.93 \pm 0.39$	0.11
Acute lumen gain, mm	1.75 ± 0.52	$1.72 \pm 0.52$	0.20
Minimum lumen diameter, mm	$2.62\pm0.42$	$2.60\pm0.38$	0.13
Diameter stenosis,	$11.3 \pm 6.6$	11.3 ± 6.4	0.87
Dissection ≥ type B	15 (1.4%)	19 (1.7%)	0.52
Slow flow or no-reflow	3 (0.3%)	6 (0.5%)	0.51
Final TIMI III flow	997/1022 (97.6%)	1000/1032 (96.9%)	0.37

#### **Conclusion**



The primary results of OCT vs. Angiography in Complex Lesions will be presented at EuroPCR - May 15, 2024